A detailed history of Prince Street Capital Management LLC transactions in Zai Lab LTD stock. As of the latest transaction made, Prince Street Capital Management LLC holds 74,500 shares of ZLAB stock, worth $2 Million. This represents 6.32% of its overall portfolio holdings.

Number of Shares
74,500
Holding current value
$2 Million
% of portfolio
6.32%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$34.2 - $51.69 $2.55 Million - $3.85 Million
74,500 New
74,500 $2.55 Million
Q1 2022

May 16, 2022

SELL
$27.77 - $64.4 $3.68 Million - $8.53 Million
-132,500 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $7.27 Million - $13.9 Million
132,500 New
132,500 $8.33 Million
Q4 2020

Feb 16, 2021

SELL
$81.94 - $135.34 $6.55 Million - $10.8 Million
-79,900 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$73.3 - $89.48 $3.98 Million - $4.86 Million
-54,300 Reduced 40.46%
79,900 $6.65 Million
Q2 2020

Aug 14, 2020

SELL
$48.82 - $82.53 $2.15 Million - $3.64 Million
-44,100 Reduced 24.73%
134,200 $11 Million
Q1 2020

May 15, 2020

SELL
$39.1 - $62.9 $1.34 Million - $2.16 Million
-34,343 Reduced 16.15%
178,300 $9.18 Million
Q4 2019

Feb 14, 2020

BUY
$29.79 - $43.06 $6.33 Million - $9.16 Million
212,643 New
212,643 $8.84 Million
Q4 2018

Feb 14, 2019

SELL
$14.95 - $24.72 $1.63 Million - $2.69 Million
-108,700 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$17.8 - $25.35 $151,300 - $215,475
-8,500 Reduced 7.25%
108,700 $2.12 Million
Q2 2018

Aug 14, 2018

BUY
$18.0 - $25.01 $75,600 - $105,042
4,200 Added 3.72%
117,200 $2.73 Million
Q4 2017

Feb 14, 2018

SELL
$21.23 - $34.09 $112,519 - $180,677
-5,300 Reduced 4.48%
113,000 $2.4 Million
Q3 2017

Nov 14, 2017

BUY
$27.0 - $31.11 $3.19 Million - $3.68 Million
118,300
118,300 $3.19 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.63B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Prince Street Capital Management LLC Portfolio

Follow Prince Street Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prince Street Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prince Street Capital Management LLC with notifications on news.